- Home
- AWH vs LIXT Comparison
AWH vs LIXT Comparison
Compare AWH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- LIXT
- Stock Information
- Founded
- AWH 1993
- LIXT 2005
- Country
- AWH United States
- LIXT United States
- Employees
- AWH N/A
- LIXT N/A
- Industry
- AWH Medical/Dental Instruments
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- AWH Health Care
- LIXT Health Care
- Exchange
- AWH Nasdaq
- LIXT Nasdaq
- Market Cap
- AWH 6.2M
- LIXT 6.3M
- IPO Year
- AWH N/A
- LIXT N/A
- Fundamental
- Price
- AWH $0.22
- LIXT $1.27
- Analyst Decision
- AWH Buy
- LIXT
- Analyst Count
- AWH 2
- LIXT 0
- Target Price
- AWH $4.40
- LIXT N/A
- AVG Volume (30 Days)
- AWH 298.1K
- LIXT 155.3K
- Earning Date
- AWH 03-27-2025
- LIXT 03-18-2025
- Dividend Yield
- AWH N/A
- LIXT N/A
- EPS Growth
- AWH N/A
- LIXT N/A
- EPS
- AWH N/A
- LIXT N/A
- Revenue
- AWH $8,963,000.00
- LIXT N/A
- Revenue This Year
- AWH $11.87
- LIXT N/A
- Revenue Next Year
- AWH $79.10
- LIXT N/A
- P/E Ratio
- AWH N/A
- LIXT N/A
- Revenue Growth
- AWH N/A
- LIXT N/A
- 52 Week Low
- AWH $0.21
- LIXT $1.25
- 52 Week High
- AWH $4.47
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- AWH 21.26
- LIXT 28.82
- Support Level
- AWH $0.21
- LIXT $1.35
- Resistance Level
- AWH $0.36
- LIXT $3.00
- Average True Range (ATR)
- AWH 0.06
- LIXT 0.26
- MACD
- AWH -0.00
- LIXT -0.13
- Stochastic Oscillator
- AWH 4.76
- LIXT 1.15
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.